ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis

被引：0
|
作者：
A Nakajima
T Tauchi
K Ohyashiki
机构：
[1] Tokyo Medical University,First Department of Internal Medicine
来源：
Leukemia | 2001年 / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：989 / 990
页数：1
相关论文
共 50 条
  • [1] ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis
    Nakajima, A
    Tauchi, T
    Ohyashiki, K
    [J]. LEUKEMIA, 2001, 15 (06) : 989 - 990
  • [2] Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells
    J Topaly
    WJ Zeller
    S Fruehauf
    [J]. Leukemia, 2001, 15 : 342 - 347
  • [3] Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells
    Kawaguchi, Y
    Jinnai, I
    Nagai, K
    Yagasaki, F
    Yakata, Y
    Matsuo, T
    Kuriyama, K
    Tomonaga, M
    [J]. LEUKEMIA, 2001, 15 (04) : 590 - 594
  • [4] Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells
    Y Kawaguchi
    I Jinnai
    K Nagai
    F Yagasaki
    Y Yakata
    T Matsuo
    K Kuriyama
    M Tomonaga
    [J]. Leukemia, 2001, 15 : 590 - 594
  • [5] Results of imatinib mesylate (STI571), a bcr-abl tyrosine kinase inhibitor, in Philadelphia chromosome-positive chronic myelogenous leukemia in blastic phase (Ph plus CML BP).
    Kantarjian, HM
    Cortes, J
    O'Brien, S
    Giles, F
    Albitar, M
    Rios, MB
    Shan, J
    Faderl, S
    Garcia-Manero, G
    Issa, JP
    Thomas, D
    Capdeville, R
    Talpaz, M
    [J]. BLOOD, 2001, 98 (11) : 260B - 260B
  • [6] Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
    Hofmann, WK
    Jones, LC
    Lemp, NA
    de Vos, S
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    Koeffler, HP
    [J]. BLOOD, 2002, 99 (05) : 1860 - 1862
  • [7] The tyrosine kinase inhibitor STI571 prolongs survival in a murine model of chronic myelogenous leukemia.
    Wolff, NC
    Xu, HM
    Zhang, SM
    Ilaria, RL
    [J]. BLOOD, 2000, 96 (11) : 344A - 344A
  • [8] STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy
    Michael J. Mauro
    Michael E. O'Dwyer
    Brian J. Druker
    [J]. Cancer Chemotherapy and Pharmacology, 2001, 48 : S77 - S78
  • [9] Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro
    Mow, BMF
    Chandra, J
    Svingen, PA
    Hallgren, CG
    Weisberg, E
    Kottke, TJ
    Narayanan, VL
    Litzow, MR
    Griffin, JD
    Sausville, EA
    Tefferi, A
    Kaufmann, SH
    [J]. BLOOD, 2002, 99 (02) : 664 - 671
  • [10] Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis
    Beham-Schmid, C
    Apfelbeck, U
    Sill, H
    Tsybrovsky, O
    Höfler, G
    Haas, OA
    Linkesch, W
    [J]. BLOOD, 2002, 99 (01) : 381 - 383
12345